Postmenopausal hormone therapy and coronary heart disease in early postmenopausal women

References

• Global atlas on cardiovascular disease prevention and control. Available at: http://whqlibdoc.who.int/publications/2011/9789241564373_eng.pdf.
   Google Scholar
• European cardiovascular disease statistics, 3rd edition, 2008. Available at: http://www.ehnheart.org/cvd-statistics.html.
   Google Scholar
• Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J. 2007;28:2028–40.
   PubMed Web of Science ®Google Scholar
• van der Schouw YT. Incidence and mortality of cardiovascular disease in postmenopausal women world-wide and relevance for preventive strategies. Climacteric. 2009;12(Suppl 1):1–5.
   PubMed Web of Science ®Google Scholar
• Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307:813–22.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–8.
   PubMed Web of Science ®Google Scholar
• Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321–9.
   PubMed Web of Science ®Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–209.
   PubMed Web of Science ®Google Scholar
• Lindquist R, Boucher JL, Grey EZ, Cairns B, Bobra S, Windenburg D, et al. Eliminating untimely deaths of women from heart disease: highlights from the Minnesota Women's Heart Summit. Am Heart J. 2012;163:39,48.e1.
   Google Scholar
• Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med. 2009; 169:1762–6.
   PubMedGoogle Scholar
• Kanter R, Caballero B. Global gender disparities in obesity: a review. Adv Nutr. 2012;3:491–8.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867–72.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53:605–19.
   PubMed Web of Science ®Google Scholar
• Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol. 2009;6:532–42.
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–37.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199–210.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–41.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA. 1998;280:605–13.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.
   PubMed Web of Science ®Google Scholar
• Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J. 2008;29:2031–41.
   PubMed Web of Science ®Google Scholar
• Stram DO, Liu Y, Henderson KD, Sullivan-Halley J, Luo J, Saxena T, et al. Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California teachers study. Menopause. 2011;18:253–61.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–61.
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61–109.
   PubMedGoogle Scholar
• Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS). Circulation. 2002;105:2962–7.
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49–57.
   PubMed Web of Science ®Google Scholar
• Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360:2001–8.
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–34.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12.
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357–65.
   PubMed Web of Science ®Google Scholar
• Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356:2591–602.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–77.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol. 2013;121:172–6.
   PubMed Web of Science ®Google Scholar
• Utian WH. NIH and WHI: time for a mea culpa and steps beyond. Menopause. 2007;14:1056–9.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348:645–50.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Clarkson TB, Notelovitz M. Postmenopausal hormone therapy before and after the Women's Health Initiative study: what consequences?Ann Med. 2004;36:402–13.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Ylikorkala O. Hormone therapy and cardiovascular disease—still much to be learnt. Gynecol Endocrinol. 2005;20:116–20.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Clarkson TB. Coronary heart disease and postmenopausal hormone therapy: conundrum explained by timing?J Womens Health (Larchmt). 2006;15:51–3.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006;15:35–44.
   PubMed Web of Science ®Google Scholar
• Ryan J, Canonico M, Carcaillon L, Carriere I, Scali J, Dartigues JF, et al. Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. PLoS One. 2012;7:e34112.
   Google Scholar
• Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583–7.
   PubMed Web of Science ®Google Scholar
• Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol. 2006;47:1741–53.
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Mehaffey MH. Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol. 2009;71:785–93.
   Google Scholar
• Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012;15:217–28.
   PubMed Web of Science ®Google Scholar
• Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13:265–79.
   PubMed Web of Science ®Google Scholar
• Archer DF. Premature menopause increases cardiovascular risk. Climacteric. 2009;12(Suppl 1):26–31.
   Google Scholar
• Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ 3rd, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16:15–23.
   PubMed Web of Science ®Google Scholar
• Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312–17.
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988;297:519–22.
   PubMed Web of Science ®Google Scholar
• Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet. 1998;352:1965–9.
   PubMed Web of Science ®Google Scholar
• Hernan MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766–79.
   PubMed Web of Science ®Google Scholar
• Kim J, Evans S, Smeeth L, Pocock S. Hormone replacement therapy and acute myocardial infarction: a large observational study exploring the influence of age. Int J Epidemiol. 2006;35:731–8.
   PubMed Web of Science ®Google Scholar
• Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008;29:2660–8.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345:e6409.
   PubMed Web of Science ®Google Scholar
• Tuomikoski P, Ylikorkala O, Mikkola TS. Menopausal hot flushes and vascular health. Ann Med. 2011;43:283–91.
   PubMed Web of Science ®Google Scholar
• Mikkola TS. The hot flush—a determinant for vascular effects of estrogen?Maturitas. 2011;69:287–8.
   Google Scholar
• Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med. 2005;23:117–25.
   PubMed Web of Science ®Google Scholar
• Archer DF, Sturdee DW, Baber R, de Villiers TJ, Pines A, Freedman RR, et al. Menopausal hot flushes and night sweats: where are we now?Climacteric. 2011;14:515–28.
   PubMed Web of Science ®Google Scholar
• van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J. 2005;26: 1358–61.
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. HRT and the young at heart. N Engl J Med. 2007;356:2639–41.
   PubMed Web of Science ®Google Scholar
• Szmuilowicz ED, Manson JE, Rossouw JE, Howard BV, Margolis KL, Greep NC, et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause. 2011;18:603–10.
   PubMed Web of Science ®Google Scholar
• Tuomikoski P, Ebert P, Groop PH, Haapalahti P, Hautamäki H, Rönnback M, et al. Effect of hot flushes on vascular function; a randomized controlled trial. Obstet Gynecol. 2009;114:777–85.
   PubMed Web of Science ®Google Scholar
• Tuomikoski P, Haapalahti P, Sarna S, Ylikorkala O, Mikkola TS. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: a placebo-controlled trial on post-menopausal hormone therapy. Ann Med. 2010;42:334–43.
   PubMed Web of Science ®Google Scholar
• Tuomikoski P, Mikkola TS, Tikkanen MJ, Ylikorkala O. Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy. Climacteric. 2010;13:457–66.
   PubMed Web of Science ®Google Scholar
• Gast GC, Pop VJ, Samsioe GN, Grobbee DE, Nilsson PM, Keyzer JJ, et al. Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms. Maturitas. 2011;70:373–8.
   Google Scholar
• Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause. 2009;16:639–43.
   PubMed Web of Science ®Google Scholar
• Svartberg J, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms and mortality: the Rancho Bernardo study. Menopause. 2009;16:888–91.
   PubMed Web of Science ®Google Scholar
• Bretler DM, Hansen PR, Sorensen R, Lindhardsen J, Ahlehoff O, Andersson C, et al. Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study. BMJ. 2012;344:e1802.
   PubMedGoogle Scholar
• Koivu TA, Fan YM, Mattila KM, Dastidar P, Jokela H, Nikkari ST, et al. The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in postmenopausal women. Maturitas. 2003;44:29–38.
   PubMed Web of Science ®Google Scholar
• Schindler TH, Campisi R, Dorsey D, Prior JO, Olschewski M, Sayre J, et al. Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors. Eur Heart J. 2009;30: 978–86.
   PubMed Web of Science ®Google Scholar
• Schenck-Gustafsson K, Brincat M, Erel CT, Gambacciani M, Lambrinoudaki I, Moen MH, et al. EMAS position statement: managing the menopause in the context of coronary heart disease. Maturitas. 2011;68:94–7.
   PubMed Web of Science ®Google Scholar
• Pines A. Post-myocardial infarction hormone therapy revisited. Climacteric. 2012;15:538–41.
   PubMed Web of Science ®Google Scholar
• Simon JA. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric. 2012;15(Suppl 1):3–10.
   PubMed Web of Science ®Google Scholar
• Purbrick B, Stranks K, Sum C, MacLennan AH. Future long-term trials of postmenopausal hormone replacement therapy - what is possible and what is the optimal protocol and regimen?Climacteric. 2012;15: 288–93.
   PubMed Web of Science ®Google Scholar
• Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3–12.
   PubMed Web of Science ®Google Scholar
• ELITE: Early versus Late Intervention Trial with Estradiol. Available at: http://clinicaltrials.gov/ct2/show/NCT00114517.
   Google Scholar
• Hormone therapy has many favorable effects in newly menopausal women: initial findings of the Kronos Early Estrogen Prevention Study (KEEPS). Available at: http://www.keepstudy.org/news/pr_100312_a.pdf.
   Google Scholar
• Kagan R. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms. J Womens Health (Larchmt). 2012;21:975–81.
   PubMed Web of Science ®Google Scholar
• Pfizer pipeline. Available at: http://www.pfizer.com/files/research/pipeline/2012_1108/pipeline_2012_1108.pdf.
   Google Scholar
• Pinkerton JV, Stovall DW. Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk?Menopause. 2009;16:219–23.
   PubMed Web of Science ®Google Scholar
• Huang Y, Malone KE, Cushing-Haugen KL, Daling JR, Li CI. Relationship between menopausal symptoms and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:379–88.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Falkeborn M, Naessen T, Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology. 1999; 10:476–80.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol. 2005;162:404–14.
   PubMed Web of Science ®Google Scholar
• Pentti K, Honkanen R, Tuppurainen MT, Sandini L, Kroger H, Saarikoski S. Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol. 2006;154:101–7.
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Brosnihan B, Herrington DM. Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on progression of coronary artery Atherosclerosis (ERA) trial. Am Heart J. 2005;150:907–11.
   PubMed Web of Science ®Google Scholar
• Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol. 2001; 21:262–8.
   PubMed Web of Science ®Google Scholar
• Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG. 2002;109:1056–62.
   PubMed Web of Science ®Google Scholar
• Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432–40.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349: 535–45.
   PubMed Web of Science ®Google Scholar
• Collins P, Flather M, Lees B, Mister R, Proudler AJ, Stevenson JC, et al. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP pilot study. Eur Heart J. 2006;27:2046–53.
   PubMed Web of Science ®Google Scholar